Citius Oncology Inc (Nasdaq:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday that it has entered into a distribution services agreement with McKesson Corporation (NYSE:MCK), a pharmaceutical distributor and healthcare services company.

Under the agreement, McKesson will serve as an authorised distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

The agreement with McKesson completes Citius Oncology's core US distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone is intended to ensure broad and reliable access to the therapy in preparation for its planned commercial launch in the fourth quarter of 2025.

LYMPHIR is a targeted immune therapy for relapsed or refractory CTCL indicated for use in Stage I-III disease after at least one prior systemic therapy. In 2021, denileukin diftitox was approved in Japan for the treatment of CTCL and PTCL. Subsequently, also in 2021, Citius acquired an exclusive licence with rights to develop and commercialise LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024.